 The FDA has cleared Sight Sciences Incs NASDAQ: SGHT TearCare System for meibomian gland dysfunction MGD, the leading cause of dry eye disease DED. The indication clears TearCare for applying localized heat therapy in adult patients with evaporative DED due to MGD when used with the manual expression of the meibomian glands. 